Thymidine Kinase-1 As A Biomarker in Breast Cancer: Estimating Prognosis and Early Recognition of Treatment Resistance

Biomarkers in MedicineVol. 14, No. 7 EditorialThymidine kinase-1 as a biomarker in breast cancer: estimating prognosis and early recognition of treatment resistanceAmelia McCartney & Luca MalorniAmelia McCartney https://orcid.org/0000-0003-0411-0736“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato, Prato, ItalySearch for more papers by this author & Luca Malorni*Author for correspondence: Tel.: +39 0574 802 520; Fax: +39 0574 802 903; E-mail Address: luca.malorni@uslcentro.toscana.it“Sandro Pitigliani” Medical Oncology Department, Hospital of Prato, Prato, Italy“Sandro Pitigliani” Translational Research Unit, Hospital of Prato, Prato, ItalySearch for more papers by this authorPublished Online:7 May 2020https://doi.org/10.2217/bmm-2020-0072AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biomarkerbreast cancerCDK4/6endocrine therapyluminal, prognosismetastaticresistancethymidine kinase-1TK1References1. Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375(20), 192–136 (2016).Crossref, Medline, Google Scholar2. Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375(18), 1738–1748 (2016).Crossref, Medline, CAS, Google Scholar3. Goetz MP, Toi M, Campone M et al. MONARCH-3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35(32), 3638–3646 (2017).Crossref, Medline, CAS, Google Scholar4. Finn RS, Crown JP, Lang I et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized Phase II study. Lancet Oncol. 16(1), 25–35 (2015).Crossref, Medline, CAS, Google Scholar5. Turner NC, Liu Y, Zhu Z et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 37(14), 1169–1178 (2019).Crossref, Medline, CAS, Google Scholar6. Finn RS, Liu Y, Zhu Z et al. Biomarker analyses of response to cyclin-dependent kinase 4/5 inhibition and endocrine therapy in women with treatment-naïve metastatic breast cancer. Clin. Cancer Res. 26(1), 110–121 (2020).Crossref, Medline, CAS, Google Scholar7. Hu CM, Chang ZF. Mitotic control of dTTP pool: a necessity or coincidence? J. Biomed. Sci. 14(4), 341–347 (2007).Crossref, Google Scholar8. Sherley JL, Kelley TJ. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem. 263(17), 8350–8358 (1988).Crossref, Medline, CAS, Google Scholar9. He Q, Zhang P, Zou L et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol. Rep. 14(4), 1013–1019 (2005).Medline, CAS, Google Scholar10. Robertson JF, O'Neill KL, Thomas MW, McKenna PG, Blamey RW. Thymidine kinase in breast cancer. Br. J. Cancer 62(4), 663–667 (1990).Crossref, Medline, CAS, Google Scholar11. Jagarlamudi KK, Shaw M. Thymidine kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker. Biomark. Med. 12(9), 1035–1048 (2018).Link, CAS, Google Scholar12. Nazari M, Gargari SLM, Sahebghadam Lotfi A, Rassaee MJ, Taheri RA. Aptamer-based sandwich assay for measurement of thymidine kinase 1 in serum of cancerous patients. Biochemistry 58(18), 2373–2383 (2019).Crossref, Medline, CAS, Google Scholar13. Nisman B, Allweis T, Kaduri L et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark. 7(2), 65–72 (2010).Crossref, Medline, CAS, Google Scholar14. Bjohle J, Bergqvist J, Gronowitz JS et al. Serum thymidine kinase activity compared with CA15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res. Treat. 139(3), 751–758 (2013).Crossref, Medline, CAS, Google Scholar15. Bonechi M, Galardi F, Biagioni C et al. Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy. Oncotarget 9(23), 16389–16399 (2018).Crossref, Medline, Google Scholar16. McCartney A, Biagioni C, Schiavon G et al. Prognostic role of serum thymidine kinase I activity in patients with hormone receptor-positive metastatic breast cancer: analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). Eur. J. Cancer 114, 55–66 (2019).Crossref, Medline, CAS, Google Scholar17. Giangrande PH, Zhu W, Rempel RE, Laakso N, Nevins JR. Combinatorial gene control involving E2F and E Box family members. EMBO J. 23(6), 1336–1347 (2004).Crossref, Medline, CAS, Google Scholar18. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol. Cell. Biol. 15(8), 4215–4224 (1995).Crossref, Medline, CAS, Google Scholar19. Stender JD, Frasor J, Komm B, Chang KC, Kraus WL, Katzenellenbogen BS. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. Mol. Endocrinol. 21(9), 2112–2123 (2007).Crossref, Medline, CAS, Google Scholar20. Bagegni N, Thomas S, Liu N et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibiton in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res. 19(1), 123 (2017).Crossref, Medline, Google Scholar21. McCartney A, Bonechi M, De Luca F et al. Plasma thymidine kinase activity as a biomarker in patients with luminal metastatic breast cancer treated with palbociclib within the TREnd trial. Clin. Cancer Res. doi:10.1158/1078-0432.CCR-19-3271 (2020) (Epub ahead of print).Crossref, Medline, Google Scholar22. Cabel L, Tanguy ML, Lerebours F et al. P5-01-12. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy. Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 10–14 December 2019.Google Scholar23. Malorni L, Migliaccio I, Biagioni C et al. P5-06-11. Serum thymidine kinase-1 activity (TKa) as a prognostic marker in premenopausal women with hormone receptor positive (HR+) operable breast cancer (BC). Presented at: San Antonio Breast Cancer Symposium, San Antonio, TX, USA 10–14 December 2019.Google Scholar24. Chen G, He C, Li L et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix. BMC Cancer 13, 249 (2013).Crossref, Medline, CAS, Google Scholar25. Xu Y, Liu B, Shi QL et al. Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung. Int. J. Clin. Exp. Med. 7(8), 2120–2128 (2014).Medline, Google Scholar26. Wang J, Liu Q, Zhou X et al. Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: a new prognostic biomarker. Tumour Biol. 39(6), 1010428317706479 (2017).Crossref, Google Scholar27. Juric D, Janku F, Rodón J et al. Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a Phase 1b clinical trial. JAMA Oncol. 5(2), e184475 (2019).Crossref, Medline, Google Scholar28. André F, Ciruelos E, Rubovszky G et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380(20), 1929–1940 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByTK1 is an early screening marker for uterine corpus endometrial carcinoma and promotes its progressionGene Reports, Vol. 31Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trialEuropean Journal of Cancer, Vol. 9 Vol. 14, No. 7 Follow us on social media for the latest updates Metrics Downloaded 160 times History Received 12 February 2020 Accepted 25 March 2020 Published online 7 May 2020 Published in print May 2020 Information© 2020 Future Medicine LtdKeywordsbiomarkerbreast cancerCDK4/6endocrine therapyluminal, prognosismetastaticresistancethymidine kinase-1TK1Financial & competing interests disclosureThis work was partially supported by a grant from the Breast Cancer Research Foundation (grant number BCRF 19-037) and by a grant from Fondazione AIRC (IG 22869). L Malorni has received research support from Novartis and Pfizer and is a consultant for Eli Lilly, Pfizer and Novartis. Both authors have academically collaborated with Biovica International without any financial remuneration or contractual agreement. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart than those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download